Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced <i>BRAF<sup>V600</sup></i>-positive melanoma: Interim analysis of the ImmunoCobiVem study.
Dirk Schadendorf(National Center for Tumor Diseases), Elisabeth Livingstone(German Cancer Research Center), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Anja Gesierich(University of Michigan), Alexander Roesch(Essen University Hospital), Katharina C. Kähler(Christian-Albrechts-Universität zu Kiel), Željko Mijušković(Military Medical Academy), Friedegund Meier(National Center for Tumor Diseases), Thomas Eigentler(University Children's Hospital Tübingen), Selma Ugurel(Klinikum Bielefeld), Dimitrios C. Ziogas(National and Kapodistrian University of Athens), Jean‐Jacques Grob(Aix-Marseille Université), Marlene Garzarolli, Lisa Zimmer(The University of Sydney), Lidija Kandolf Sekulović(Military Medical Academy), Helen Gogas(National and Kapodistrian University of Athens), Claus Garbe(University of Tübingen), Jan‐Christoph Simon(Leipzig University), Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k